Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215 by Szereday, Z et al.
Effective treatment of experimental U-87MG human glioblastoma
in nude mice with a targeted cytotoxic bombesin analogue,
AN-215
Z Szereday
1,2, AV Schally*
,1,2, A Nagy
1,2, A Plonowski
1,2, AM Bajo
1,2, G Halmos
1,2, K Szepeshazi
1,2 and
K Groot
1
1Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, 1601 Perdido Street, New Orleans, Louisiana, LA 70112-1262, USA;
2Section of
Experimental Medicine, Department of Medicine, Tulane University School of Medicine, 1601 Perdido Street, New Orleans, Louisiana, LA 70112-1262,
USA
Some brain tumours, such as glioblastomas express high levels of receptors for bombesin/gastrin releasing peptide. We
investigated whether bombesin/gastrin releasing peptide receptors found in glioblastoma cell lines can be utilised for targeting
of a cytotoxic bombesin analogue, AN-215 consisting of a potent derivative of doxorubicin, 2-pyrrolino-doxorubicin (AN-201)
linked to a bombesin-like peptide carrier. This study reports the effect of AN-215 on the growth of U-87MG human
glioblastomas xenografted into nude mice. High afﬁnity binding of AN-215 to U-87MG tumours was characterised by an IC50
value of 4.0+0.1 nM, as determined by radioreceptor assays. mRNA analyses revealed the presence of mRNA for BN
receptor subtypes 1 and 2. Treatment with AN-215 signiﬁcantly (P50.05) extended tumour doubling time from 4.54+0.2
days to 8.18+1.8 days and inhibited tumour growth as demonstrated by a 69.6% reduction in ﬁnal tumour volume (P50.001)
and a 64.6% decrease in tumour weight as compared to controls. Cytotoxic radical AN-201 at the same dose was ineffective.
The antitumour effect of AN-215 could be blocked by pretreatment with an excess of a bombesin antagonist, indicating that
the action of this cytotoxic analogue is receptor-mediated. Our results suggest that patients with inoperable brain tumours
such as malignant gliomas may beneﬁt from targeted chemotherapy based on cytotoxic bombesin analogue AN-215.
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About 17000 Americans develop primary brain tumours and
13000 die from them each year (Greenlee et al, 2000). The annual
incidence rates of primary brain tumours in the United Kingdom,
France, Norway and Finland and mortalities per 100000 popula-
tion are similar to those in the United States (Muir et al, 1994;
Fleury et al, 1997; Prados and Levin, 2000). The incidence of brain
cancer may be increasing in older people (Muir et al, 1994). Glio-
blastoma multiforme is the most common type of primary
malignant CNS tumours in adults and is considered incurable
(Hochberg and Pruitt, 1987).
Current treatment options for malignant gliomas, including
surgery, radiation, and chemotherapy, are of limited effectiveness,
and novel therapeutic modalities must be explored. Targeting of
antineoplastic agents to cancer cells by linking them to a ligand
with high afﬁnity for tumour cells should improve tumour growth
inhibition and decrease peripheral toxicity (Schally and Nagy,
1999). The presence of high afﬁnity receptors for bombesin
(BN)-like peptides on a wide variety of tumours prompted us to
employ some of our powerful BN/gastrin releasing peptide (GRP)
antagonists as carrier molecules for targeting cytotoxic agents to
tumour cells (Nagy et al, 1997). One of these cytotoxic BN conju-
gates, AN-215 (Nagy et al, 1997) consists of a potent cytotoxic
derivative of doxorubicin (DOX), 2-pyrrolino-DOX (AN-201)
(Nagy et al, 1996), covalently linked through a glutaric acid spacer
to the amino terminal of Gln-Trp-Ala-Val-Gly-His-Leu-c-Leu-
NH2, a BN-like peptide carrier (Nagy et al, 1997). AN-215 displays
high afﬁnity to BN receptors on Swiss 3T3 ﬁbroblasts and retains
the antiproliferative effect of its cytotoxic moiety (Nagy et al,
1997). This cytotoxic conjugate was shown to effectively inhibit
BN receptor-positive neoplasms, including H-69 human small-cell
lung carcinoma (Kiaris et al, 1999a) and PC-3 human androgen-
independent prostate cancer (Plonowski et al, 2000).
In view of ﬁndings that 85% of human glioblastoma cell lines
express functional receptors for BN/GRP (Moody et al, 1989; Staley
et al, 1993; Pinski et al, 1994; Sharif et al, 1997), we evaluated in
this study the efﬁcacy of targeted chemotherapy based on cytotoxic
analogue of BN, AN-215 in U-87MG human glioblastoma xeno-
grafted into nude mice.
MATERIALS AND METHODS
Peptide and cytotoxic agents
Cytotoxic conjugate AN-215 was made by coupling one molecule
of 2-pyrrolino-DOX-14-O-hemiglutarate to the amino terminus
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NH)-Leu-NH2 as described (Nagy et al, 1997). GRP(14-27), cyto-
toxic radical AN-201 (Nagy et al, 1996) and BN/GRP antagonist
RC-3095 [D-Tpi
6,Leu
13c(CH2NH)Leu
14]BN (6-14) (Radulovic et
al, 1991) were also synthesised in our laboratory. For intravenous
(i.v.) injection, the compounds were dissolved in 20 ml of 0.01 N
acetic acid and diluted with 5% (w v
71) aqueous D-mannitol
(Sigma, St. Louis, MO, USA) solution.
Cell lines, animals and tumours
Human glioblastoma cell line U-87MG was obtained from American
Type Culture Collection (Manassas, VA, USA) and cultured as
described (Pinski et al, 1994). Male athymic (Ncr nu/nu) nude mice,
approximately 6-weeks-old on arrival, were obtained from the
National Cancer Institute (Frederick Cancer Research and Develop-
ment Center, Frederick, MD, USA), and housed in laminar air-ﬂow
cabinets under pathogen-free conditions with a 12 h light/12 h dark
schedule, and fed autoclaved standard chow and water ad libitum.
Xenografts were initiated by s.c. injection of 12610
6 U-87MG cells
into the right ﬂanks of ﬁve male nude mice. Tumours resulting after
2 weeks were aseptically dissected, mechanically minced, and 3-mm
3
pieces of tumour tissue were transplanted s.c. with a trocar needle.
The take rate was 100%. All experiments were performed in accor-
dance with institutional ethical guidelines of animal care and were
essentially in agreement with UKCCCR guidelines (1998) for the
welfare of animals in experimental neoplasia.
Experimental protocols
Experiment 1 was started when tumours had grown to approxi-
mately 40 mm
3 in volume. Animals were randomly divided into
three treatment groups: group 1(10 mice), control, which received
vehicle solution; group 2 (10 mice), injected with cytotoxic radical
AN-201; group 3 (11 mice), given cytotoxic BN analogue AN-215.
Cytotoxic compounds were injected through the jugular vein at a
dose of 150 nmol kg
71 of body weight (BW) on days 1, 8, 15
and 22. Tumour volume (length6width6height60.5236) and
BW were measured twice a week. The experiment was terminated
on day 29. Blood samples were collected from the inferior vena
cava under Metofane (Malinkrodt Vet. Mundelein, IL, USA) anaes-
thesia and then Metofane was used in overdose to sacriﬁce the
mice. Tumours were excised and weighed. Tumour specimens were
snap-frozen and stored at 7708C until extraction of RNA for
reverse transcription-polymerase chain reaction (RT–PCR).
Tumour volume doubling time was calculated between day 1 and
29 using the formula:
days of treatment
log final volÿlog initial volume=log2
as described by Smolev et al (1977).
Experiment 2 was started when U-87MG tumours had grown to
70–84 mm
3 in volume. The animals were divided into the follow-
ing treatment groups: group 1 (10 mice), control, vehicle solution;
group 2 (10 mice), analogue AN-215; group 3 (ﬁve mice), uncon-
jugated mixture of the cytotoxic radical AN-201 and BN antagonist
RC-3095. All compounds were injected i.v. at 150 nmol kg
71 of
BW on days 1, 10, and 17. In addition, one group of tumour-bear-
ing mice received an i.v. injection of 200 mg of BN antagonist RC-
3095 15 min before each administration of AN-215 at a dose of
150 nmol kg
71 of BW on days 1, 10 and 17 as in the case of group
2. The experiment was terminated on day 20 as described above.
Evaluation of toxicity
General toxicity was evaluated on the basis of mortality rate and
changes in BW. Toxicity to BN receptor-positive organs was
assessed by measuring gastrin release in response to GRP stimula-
tion (Plonowski et al, 2000). At the end of experiment 1, blood
samples were collected 5 min after i.v. injection of 2 mgo f
GRP(14-27) dissolved in 100 ml of 5% mannitol. Serum gastrin
concentrations were measured by double-antibody radioimmu-
noassay with a kit provided by ICN Pharmaceuticals Diagnostic
Division (Orangeburg, NY, USA). The interassay variation was
10.6%, and the intraassay variation was 6%.
Histological methods
Samples of tumour tissues were ﬁxed in 10% buffered formalin.
The specimens were embedded in Paraplast (Oxford Labware, St.
Louis, MO, USA). Six mm thick sections were cut and stained with
haematoxylin-eosin. Mitotic and apoptotic cells were counted in
nine standard high power microscopic ﬁelds containing an average
of 330 cells, and their numbers per 1000 cells were accepted as the
mitotic and apoptotic indices, respectively. To eliminate errors
caused by variances in thickness of slides and cellularity of areas
investigated, the ratio of apoptotic to mitotic indices was calculated
in each tumour. For the determination of the extent of necrosis in
tumours, the crossing points of a microscope ocular net that coin-
cided with necrosis in the slide made at the largest cross-section of
each tumour were counted. The ratio of these points to the
number of all points above the tumour represented the percentage
area of necrosis. For demonstration of the nucleolar organiser
region (NOR) in tumour cell nuclei, the AgNOR method was used
(Szepeshazi et al, 1991). NORs are parts of DNA closely associated
with nucleoli and encode for ribosomal RNA. They are also asso-
ciated with argyrophylic proteins and thus can be visualised by
silver staining. The amount of AgNORs is a good indicator of cell
proliferation (van Diest et al, 1998). The silver-stained black dots
in 50 cells of each tumour were counted and the AgNOR number
per cell was calculated. The data were evaluated by one way analy-
sis of variance (ANOVA) and the treated groups compared to the
control by Dunnett’s test.
RNA extraction and RT–PCR
Total RNA was extracted from frozen tissue samples by using
RNAzolB (Tel-Test, Friendswood, TX, USA) according to the
manufacturer’s instructions. Concentrations of total RNA were
calculated by measuring the OD260 value. Total RNA (4 mg) was
subjected to electrophoresis for 2 h at 70 V in 10 ml of sample
buffer containing 16 MOPS buffer (pH 6.5), 6.4% formaldehyde,
48% deionized formamide, 0.25% w v
71 bromophenol blue, 0.05%
glycerol and 0.25 mg ml
71 ethidium bromide. The RNA gel
contained 1.4% agarose, 16MOPS (pH 6.5) and 1.73% formalde-
hyde.
The RT–PCR was performed using Gene Amp RNA Core Kit
(Perkin-Elmer, Foster City, CA, USA). To avoid genomic DNA
contamination, all samples were subjected to DNase digestion
before RT–PCR. RNA (2 mg) was treated with 0.3 unit of RQ1
RNase-free DNase (Promega, Madison, WI, USA) at 378C for
30 min in 19 ml of mixture containing 5 mM MgCl2,1 6 PCR
buffer, 1 mM of each dNTP, 1 unit RNase inhibitor and 2.5 mM
random hexamers. The reaction was terminated by enzyme dena-
turation at 998C for 5 min. After cooling, 2.5 units of murine
leukaemia virus (MuLV) reverse transcriptase was added and RT
was carried out at 428C for 30 min.
The PCR ampliﬁcation of the cDNAs for human glyceraldehyde-
3-phosphate dehydrogenase (hGAPDH), GRP receptor (hGRPR,
BRS-1) and neuromedin-B receptor (hNMBR, BRS-2) was
performed as follows. Two ml of the cDNA were ampliﬁed in a
25-ml solution containing: 2 mM MgCl2,1 6 PCR buffer, 200 mM
of each dNTP, 2.5 units of Ampli Taq DNA polymerase and
0.2 mM of each primer. The primers used were 5'- TCC TCT
GAC TTC AAC AGC GAC ACC-3' and 5'-TCT CTC TTC CTC
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TGG CTG C-3' and 5'-TGA GGC AGA TCT TCA TCA G-3' for
hGRPR, 5'- CGG ACT CTG CTG GAA AGG A-3' and 5'-GAC
GTC TGC ATG TCC ATG G-3' for hNMBR (Kiaris et al,
1999b). Samples were denatured at 948C for 5 min and then
subjected to 30 cycles for hGAPDH or 40 cycles for hNMBR of
948C for 30 s, 608C for 30 s and 728C for 40 s or 35 cycles for
hGRPR of 948C for 1 min, 588C for 1 min and 728C for 1 min,
followed by a ﬁnal extension at 728C for 7 min using a Perkin-
Elmer DNA thermal cycler model 2400. The number of cycles
was determined in preliminary experiments to be within the expo-
nential range of PCR ampliﬁcation. Negative controls using
distilled water instead of cDNA in the PCR mixture were run in
parallel to exclude genomic DNA contamination. Aliquots of each
PCR product were subjected to electrophoresis on a 2% agarose
gel, stained with ethidium bromide and visualised under ultraviolet
light. For the quantitation of PCR-ampliﬁed products, a scanning
densitometer (model GS-700, Bio-Rad) coupled with the Bio-Rad
personal computer analysis software was used. All experiments
were repeated at least twice and similar results were obtained.
The relative mRNA levels of each gene were normalised vs the
corresponding levels of hGAPDH.
Receptor binding assays
Binding characteristics of BN receptors on membrane preparations
from U-87MG tumours were determined by ligand competition
assays using
125I-labelled [Tyr
4]BN, as reported earlier (Halmos
and Schally, 1997). Receptor binding afﬁnity of cytotoxic BN
analogue AN-215 to tumour membranes was measured in displace-
ment experiments based on competitive inhibition of
125I-[Tyr
4]BN
binding, using various concentrations of AN-215 (10
76–10
712 M).
IC50 value was calculated with a computerized curve ﬁtting
programme and is deﬁned as the concentration of AN-215 causing
a 50% inhibition of
125I-[Tyr
4]BN binding.
Statistical analysis
Data are expressed as mean+s.e. Differences between mean values
were evaluated by two-tailed Student’s t-test, P50.05 being consid-
ered signiﬁcant.
RESULTS
Inhibition of tumour growth by AN-215
Experiment 1 was designed to compare the antitumour effects and
toxicity of cytotoxic BN analogue AN-215 and its cytotoxic radical
AN-201. A treatment regimen consisting of four i.v. injections of
AN-215 at 150 nmol kg
71 of BW produced a strong tumour
growth inhibition (Figure 1). The inhibitory effect of AN-215
was evident within 6 days and became signiﬁcant from day 11.
Four weeks after the initiation of the treatment, the tumour
doubling time in animals treated with AN-215 was signiﬁcantly
prolonged from 4.5+0.2 to 8.2+1.8 days (P50.05) (Table 1).
In contrast, tumour doubling time in mice given an equimolar
dose of AN-201 was 5.9+1.4 days which did not differ signiﬁcantly
from the controls. Tumour volume and weight are shown in Table
1.
In experiment 2, the treatment was initiated when xenografts of
U-87MG glioblastomas had grown to a volume, approximately
twice as large as that in experiment 1. After 20 days the tumour
doubling time in mice treated with three i.v. injections of AN-
215 was extended signiﬁcantly (P50.05) to 6.6+1.0 days
compared to the control group, which came to 4.5+0.2 days.
The changes in tumour volume are presented in Figure 2.
Effect of blockade of BN receptors
As part of experiment 2, mice bearing U-87MG tumours were
pretreated i.v. with a high dose of BN antagonist RC-3095
(200 mg/mouse) to block BN receptors prior to each administration
of AN-215. As shown in Figure 2, the pretreatment with RC-3095
attenuated the antitumour effect of the cytotoxic BN analogue AN-
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Table 1 The effects of cytotoxic analogue of BN AN-215 and its cytotoxic radi-
cal AN-201 on tumour growth of U-87MG glioblastomas xenografted into nude
mice
Final tumour Tumour Tumour
Group and Initial tumour volume (mm
3) doubling weight (mg)
treatment
a volume (mm
3) (% inhibition) time (days) (% inhibition)
Control 39.7+3.8 3201.5+375.7 4.5+0.2 3050+0.4
AN-201 37.7+6.3 2353.7+506.7 5.9+1.4 2650+0.5
d
(26%) (13.2%)
AN-215 35.5+5.2 971.5+227.9
b 8.2+1.8
c 1080+0.3
b
(69.6%) (64.6%)
aIntravenous, injections of 150 nmol kg
71 of BW of each compound were administered on
days 1, 8, 15 and 22. The experiment was terminated on day 29. The values are
means+s.e.
bP50.001 vs control.
cP50.05 vs control.
dP50.05 vs AN-215.
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Figure 1 The effects of cytotoxic BN analogue AN-215 and cytotoxic
radical AN-201 on the growth of s.c. xenografts of U-87MG human glio-
blastoma in nude mice (experiment 1). The treatment consisting of four
i.v. injections of the respective compounds at 150 nmol kg
71 of BW,
was started when tumour volume reached approximately 40 mm
3 (arrows
indicate the days of injections; vertical bars show s.e.).
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tumour doubling time was 4.7+02 days, close to control data.
Toxicity
In experiment 1, two of 10 animals (20%) died in the group that
received AN-201, but only one of 11 animals (9%) died after treat-
ment with AN-215. To estimate the side effects caused by targeting
the cytotoxic agent to normal organs that express GRP/BN recep-
tors, we evaluated the effect of AN-201 and AN-215 on the serum
concentration of gastrin following i.v. stimulation with GRP(14-27)
at the end of the experiment. Neither AN-215 nor AN-201 affected
GRP-stimulated gastrin release (Table 2).
In experiment 2, two of ﬁve animals died (40%) in the group
that received an unconjugated mixture of AN-201 and RC-3095
and one of nine animals (11%) died in the group that received
an i.v. injection of 200 mg of BN antagonist RC-3095 about
15 min before administrations of AN-215, but no toxicity-related
deaths occurred during the experiment in the AN-215-treated
group. One of 11 animals (9%) died in the control group on the
day when the experiment was terminated.
Histology
Histologically, U-87MG glioblastomas are highly cellular tumours
consisting of relatively large undifferentiated cells showing a
moderate polymorphism. The cells have narrow cytoplasms and
round or oval nuclei with loose chromatin structure and promi-
nent nucleoli. At some areas, there are more elongated cells
arranged in large bundles. The quantitative histological data are
shown in Table 3. The extent of necrosis in the tumours treated
with AN-215 was signiﬁcantly larger than in the controls, while
AN-201 caused only a slight and not signiﬁcant change in necrosis.
The mean mitotic and apoptotic indices were not appreciably
changed by the treatments. However, a slight decrease in mitosis
and an increase in apoptosis in the tumours treated with AN-215
resulted in a signiﬁcant elevation of the ratio of apoptotic to mito-
tic indices.
Expression of mRNAs for GRP/BN receptors
The total RNA isolated from control and treated samples was run
on formaldehyde agarose gel. As expected, there were only two
intense bands, corresponding to the 28S and 18S rRNAs indicating
that the total RNA was intact (data not shown). The levels of
mRNA for BN/GRP receptor subtypes hGRPR/BSR1 and
hNMBR/BRS-2 were analysed in U-87MG tumours of all groups
in experiment 1 (Figure 3). Densitometric analyses of RT–PCR
products revealed that hGRPR/BRS-1 mRNA expression was
15.1+1.5 arbitrary units (a.u.) in the control group and
21.6+3.4 a.u. and 25.4+5.1 a.u. in the AN-201- and AN-215-
treated groups, respectively; the increase in both treated groups
being not signiﬁcant. The hNMBR/BRS-2 mRNA expression was
7.6+3.5 a.u. in the control group and 10.9+3.6 a.u. and
3.3+1.0 a.u. in the AN-201- and AN-215-treated groups, respec-
tively. The decrease in the AN-215 group was again not
statistically signiﬁcant. No corresponding PCR products were
detected from the negative control, indicating that the PCR
products generated from cDNA, and not from genomic DNA
contamination. PCR products with the expected size of 207 bp
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
e8
e7
e6
e5
e4
N
a
t
u
r
a
l
 
l
o
g
 
o
f
 
t
u
m
o
u
r
 
v
o
l
u
m
e
0                        5                       10                       15                      20
Days of treatment
Control
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Receptor blockade 3´(200 µg RC-3095 + 150 nmol kg
–1 AN-215)
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–1
Figure 2 Evaluation of the antitumour effect of AN-215 in animals pre-
treated or not with 200 mg of BN antagonist RC-3095 15 min before ad-
ministration of AN-215 at a dose of 150 nmol kg
71 to block the receptor-
mediated uptake of the conjugate. Effects of an unconjugated mixture of
cytotoxic radical AN-201 and RC-3095 are also shown. (Arrows indicate
the days of injections; vertical bars show s.e.).
Table 2 Tolerance of nude mice bearing s.c. xenografts of U-87MG hu-
man glioblastomas to cytotoxic BN analogue AN-215, cytotoxic radical
AN-201 and the mixture of RC-3095 and AN-201
Group Final BW, GRP(17-24)-evoked
and g (% of serum gastrin level
treatment Mortality
a control) (pg ml
71)
Control (Experiment 1) 0/10 29.3+1.0 223.0+17.9
AN-201 2/10 25.5+0.8 (86%) 251.5+22.1
AN-215 1/11 25.4+0.6 (87%) 257.9+11.6
Control (Experiment 2) 1/10 30.2+0.8 ND
b
AN-215 0/10 27.3+0.9 (90%) ND
b
Mixture of AN-201 and 2/5 27.1+1.6 (89%) ND
b
RC-3095
RC-3095 and AN-215
c 1/9 29.6+0.8 (98%) ND
b
aNumber of dead animals/number of total.
bND=Not determined.
cRC-3095 was
injected 15 min prior to AN-215 to block the receptors for BN.
Table 3 The effects of treatment with cytotoxic BN analogue AN-215 and cytotoxic
radical AN-201 on the histological characteristics of U-87MG human glioblastomas in
nude mice
Number of Ratio of Number of
tumours % area of Mitotic Apoptotic apoptotic to AgNORs
Group evaluated necrosis index index mitotic indices per cell
1 Control 9 60.0+5.8 16.6+1.4 5.9+0.7 0.38+0.06 4.93+0.18
2 AN-201 7 69.6+7.0 15.2+1.5 5.3+0.6 0.36+0.04 4.31+0.09*
3 AN-215 9 81.7+6.7* 10.9+2.2 6.2+0.8 0.85+0.25* 4.16+0.12*
The values are means+s.e. *P50.05 vs control.
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ing that no RNA degradation occurred during the preparations.
Radioreceptor assays
In the control group, radiolabelled [Tyr
4]BN was bound to a single
class of speciﬁc binding sites with high afﬁnity (Kd=5.36+
0.69 nM), and low capacity (Bmax=362.7+11.3 fmol mg
71
membrane protein). Speciﬁc high afﬁnity binding sites for BN/
GRP were also found on the AN-215-treated tumours (Kd=
5.98+0.91 nM,B max=362.6+8.6 fmol mg
71 membrane protein).
Thus, the treatment with AN-215 did not affect the binding char-
acteristics of receptors for BN/GRP in U-87MG human
glioblastoma.
The concentration of unlabelled AN-215 required to inhibit 50%
of the speciﬁc
125I-[Tyr
4]BN binding (IC50) was 4.0+0.1 nM. This
IC50 value of AN-215 represents a high binding afﬁnity to BN/GRP
receptor protein expressed on U-87MG tumours.
DISCUSSION
Chemotherapy is still one of the major modalities for the treatment
of inoperable malignancies or for adjuvant therapy after surgery.
However, the use of antineoplastic agents is hampered by their
non-speciﬁc toxicity to normal, healthy tissues and intrinsic or
acquired chemoresistance of cancerous cells. The targeting of
chemotherapeutic agents speciﬁcally to tumour sites is a modern
approach that may help overcome some of these drawbacks
(Schally and Nagy, 1999).
Recently, we developed a series of targeted cytotoxic conjugates
based on analogues of peptide hormones such as luteinizing
hormone-releasing hormone(LH-RH), somatostatin and BN/GRP,
for which high afﬁnity receptors are expressed on a variety of
tumours (Schally and Nagy, 1999; Nagy and Schally, 2001). DOX
or its intensely potent derivative, 2-pyrrolino-DOX (AN-201),
which is 1000 times more potent than DOX in vitro, were linked
through their 14-O-glutaryl esters to a free amino group in the
peptide carriers to form conjugates which retained cytotoxic activ-
ity and high binding afﬁnity to respective receptors. LH-RH
analogue AN-207 containing cytotoxic radical AN-201 also strongly
inhibits DOX-resistant MX-1 human breast cancers in vivo (Kahan
et al, 1999), indicating that 2-pyrrolino-DOX is non-cross-resistant
with DOX, in analogy with similar highly potent derivatives of
DOX such as Nemorubicin (Nagy and Schally, 2001). In addition,
we demonstrated that the presence of receptors for somatostatin on
U-87MG human glioblastomas can be utilised for an improvement
in therapeutic efﬁcacy when the targeted cytotoxic somatostatin
analogue AN-238 which contains AN-201 is used, but not its coun-
terpart containing DOX (Kiaris et al, 2000).
It has been shown that a high percentage of brain tumour cell
lines, including U-87MG, express receptors for BN/GRP (Sharif et
al, 1997). In our study we evaluated the effects of targeted therapy
of U-87MG human glioblastoma xenografted into nude mice
utilising one of our cytotoxic BN-like conjugates, AN-215
containing AN-201. The results of experiment 1 indicate, that
similarly to somatostatin receptors, BN/GRP receptors on brain
tumours can also be employed for the targeting of conjugates
containing the highly potent derivative of DOX, AN-201 in order
to improve the efﬁcacy and lower its toxicity. This ﬁnding is in
agreement with our previous results on PC-3 human androgen
independent prostate cancers and H-69 small cell lung cancers,
which indicated that improved efﬁcacy can be achieved by target-
ing AN-201 to receptors for somatostatin or BN/GRP. To
corroborate the concept that AN-215 acts through the binding
to receptors for BN on U-87MG tumours, we designed a second
experiment, in which an excess of the BN antagonist RC-3095 was
injected i.v. 15 min before the administration of AN-215 in order
to block the receptors for BN. As anticipated, the blockade of BN
receptors signiﬁcantly lowered the antitumour activity of AN-215
resulting only in a non-signiﬁcant growth inhibition of U-87MG
glioblastomas, similar to that produced by AN-201. This insignif-
icant effect is probably due to the fact that the blockade of the
BN receptors caused a longer exposure of AN-215 to non-speciﬁc
carboxylesterase enzymes (EC3.1.1.) in the circulation, which can
release the cytotoxic radical before the targeting is completed
(Nagy et al, 2000). Preclinical and clinical results with new radi-
oligands, developed for BN-receptor scintigraphy, also indicate
that BN analogues can accumulate in BN receptor-positive
tumours, further supporting the theory that BN receptors can
be used for targeted chemotherapy (Breeman et al, 1999; Van
de Wiele et al, 2000).
Binding assays using
125I-labelled[Tyr
4]BN conﬁrmed the
presence of BN/GRP receptors on U-87MG tumour membranes
(Pinski et al, 1994) and demonstrated a high afﬁnity binding of
AN-215 to these receptors characterised by an IC50 value of
4.0+0.1 nM. RT–PCR analyses also conﬁrmed previous ﬁndings
that these tumours express mRNAs for BN receptor subtype 1
and 2 but not for the orphan receptor subtype 3 (Kiaris et al,
1999b)
Histological analysis showed that treatment with AN-215, but
not with cytotoxic radical AN-201, increased signiﬁcantly the area
of necrosis and the ratio of apoptotic to mitotic indices in U-
87MG tumours. This can be explained by a higher accumulation
of the cytotoxic radical in tumour tissue after treatment with
AN-215, as a result of targeting. The histological data also suggest
that such accumulation of AN-201 can cause cell death through
necrosis, which may be preferable in cancer therapy to that caused
by apoptosis (Kiaris and Schally, 1999).
In our previous study (Plonowski et al, 2000) we reported that
after the ﬁnal injection of AN-215, AN-201 or the mixture of AN-
201 and RC-3094 there was an approximate 50% reduction in
WBC count in nude mice bearing PC-3 human prostate cancers.
This decrease in WBC was accompanied by a transient decrease in
BW. In the present study no measurements of WBC were carried
out. Instead, the assessment of toxicity was based on changes in
BW and mortality which indicated, in both experiments, that
targeted cytotoxic BN analogue AN-215 is not toxic (Table 2).
In experiment 1, two of 10 animals (20%) died after four conse-
cutive injections of AN-201 at 150 nmol kg
71 of BW dose but,
one of 11 mice (9%) also died receiving the same dose of AN-
215. This toxicity of AN-215 can be explained by the fact that
the activity of esterase enzymes in the serum of nude mice is very
high, about six times higher than in humans, causing a partial
release of AN-201 before the targeting is completed (Nagy et al,
2000). This phenomenon can also account for the death of one
of nine animals in experiment 2, in which a high dose of BN
antagonist RC-3095 was injected into nude mice to block BN
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Figure 3 Agarose gel electrophoresis of reverse-transcribed and PCR-
ampliﬁed mRNAs for hGRPR/BRS-1 and hNMBR/BRS-2 in U-87MG tu-
mours in nude mice. The bands for the corresponding hGAPDH are also
shown. M, DNA size marker; 7, negative control; 1–3, untreated tumours;
4–6, AN-201-treated tumours; 7–9, AN-215-treated tumours. All PCR-
ampliﬁcation reactions yielded products of the expected size, which were
158 bp for hGRPR/BRS-1, 484 bp for hNMBR/BRS-2 and 207 bp for
hGAPDH.
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150 nmol kg
71 of BW. The blockade of BN receptors would inhi-
bit receptor-mediated accumulation of AN-215 in BN receptor-
positive tissues, and the extended time of AN-215 in the circula-
tion can cause the release of a high percentage of AN-201 from
the conjugate. In this experiment, no deaths occurred in the
group treated with the same dose of AN-215 without pretreat-
ment with RC-3095. In further support of this view, a
signiﬁcantly higher tolerance to AN-215 by nude mice was
demonstrated when carboxylesterase enzymes were inhibited
(Nagy et al, 2000; Plonowski et al, 2000). Because receptors for
BN are also expressed in various normal tissues such as the
CNS, lungs, pancreas, breast, prostate or the gastrointestinal tract,
it is assumed that there is a competition for targeted cytotoxic
conjugate AN-215 between normal and cancerous tissues. Our
previous results indicate that despite this competition, AN-215
is highly efﬁcacious even in nude mice with suppressed esterase
activity (Plonowski et al, 2000). In this study and also in our
previous work (Plonowski et al, 2000), we found that AN-215
caused no speciﬁc damage to the gastrointestinal cells as deter-
mined by GRP-stimulated gastric secretion.
In conclusion, the present study demonstrates that cytotoxic BN
analogue AN-215 is not toxic and signiﬁcantly more effective in
inhibiting the growth of U-87MG human glioblastomas than its
non-targeted cytotoxic radical AN-201. Because receptors for BN/
GRP are present on a high percentage of human glioblastoma cell
lines, it is likely that further studies with AN-215 followed by ther-
apeutic trials could result in the development of a new therapeutic
approach for the management of patients suffering from advanced
glioblastomas.
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